Agenus (AGEN)
NASDAQ:AGEN
Want to see AGEN full AI Analyst Report?
Top Page
Agenus
(NASDAQ:AGEN)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.50
▼(-3.02% Downside)
Action:ReiteratedDate:04/11/26
The score is held down primarily by weak financial performance (negative equity and significant ongoing cash burn) and unfavorable valuation (very high P/E). Technicals are moderately supportive in the near term, and corporate events reduce risk and improve strategic positioning, but they do not fully offset the underlying financial strain.
Positive Factors
Strategic partnerships & asset sale
Agenus's Zydus collaboration, asset sale and equity investment provide durable strategic benefits: immediate manufacturing access, partnership funding and operational support that can extend runway and de-risk execution for clinical programs, improving commercialization prospects over months.
Negative Factors
Persistently negative shareholder equity
Negative shareholder equity across multiple years weakens the company’s financial buffer, complicates covenants and future financings, and increases dilution risk. It constrains capital structure options and raises the sensitivity to adverse operational or market shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic partnerships & asset sale
Agenus's Zydus collaboration, asset sale and equity investment provide durable strategic benefits: immediate manufacturing access, partnership funding and operational support that can extend runway and de-risk execution for clinical programs, improving commercialization prospects over months.
Read all positive factors
Agenus (AGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$185.46M
Dividend YieldN/A
Average Volume (3M)793.99K
Price to Earnings (P/E)811.9
Beta (1Y)3.13
Revenue Growth-33.41%
EPS Growth81.19%
CountryUS
Employees316
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding38,398,354
10 Day Avg. Volume1,303,385
30 Day Avg. Volume793,994
Financial Highlights & Ratios
PEG Ratio-8.12
Price to Book (P/B)-0.34
Price to Sales (P/S)0.82
P/FCF Ratio-0.59
Enterprise Value/Market Cap2.75
Enterprise Value/Revenue4.47
Enterprise Value/Gross Profit12.52
Enterprise Value/Ebitda7.17
Forecast
1Y Price Target
$23.00Price Target Upside395.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.56
Revenue Forecast (FY)$232.45M
Agenus Business Overview & Revenue Model
Company Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully ...
How the Company Makes Money
Agenus primarily generates revenue from collaboration and licensing arrangements rather than from product sales, as it is a clinical-stage company. Key revenue streams can include (1) upfront payments and option fees received when it enters strate...
Agenus Earnings Call Summary
Earnings Call Date:May 12, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted several positive developments, including strategic hires, promising BOT/BAL data, and multiple capital proposals which could strengthen the company's financial position. However, financial metrics such as a decreased cash balance and lower revenue compared to the previous year, alongside ongoing regulatory challenges, present notable challenges. The overall sentiment is cautiously optimistic as the highlights and lowlights are balanced.Positive Updates
Operational Efficiency Goals
Agenus is on track to reduce its operational cash burn to below $50 million annualized in the second half of 2025.
Negative Updates
Decrease in Cash Balance
The company ended Q1 2025 with a cash balance of $18.5 million, down from $40.4 million at the end of 2024.
Read all updates
Q1-2025 Updates
Positive
Negative
Operational Efficiency Goals
Agenus is on track to reduce its operational cash burn to below $50 million annualized in the second half of 2025.
Read all positive updates
Company Guidance
During Agenus Inc.'s First Quarter 2025 Earnings Conference Call, the company outlined several strategic priorities, focusing on their innovative BOT/BAL data, operational efficiencies, and impending transactions to enhance financial strength. They aim to reduce operational cash burn to below $50 million annually by the second half of 2025. The company's financials for the first quarter showcased a cash balance of $18.5 million, a reduction from $40.4 million at the end of 2024, with a net loss of $26.4 million or $1.03 per share. Revenue was reported at $24.1 million, primarily from non-cash royalty revenue. Agenus has received four transaction proposals, including a potential Emeryville facility sale and two BOT/BAL licensing deals, aimed to bolster their balance sheet. The call emphasized the wide-reaching potential of BOT/BAL in treating cold tumors, with promising data from recent studies, and discussed the evolving regulatory landscape that could expedite therapy approvals.Agenus Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 114.20M | 103.46M | 156.31M | 98.02M | 295.67M |
| Gross Profit | 103.17M | -52.55M | -81.37M | -99.23M | 113.59M |
| EBITDA | -10.56M | -101.30M | -145.92M | -161.85M | 43.78M |
| Net Income | 115.00K | -227.21M | -245.76M | -220.07M | -23.93M |
Balance Sheet | |||||
| Total Assets | 226.80M | 226.27M | 313.91M | 413.56M | 465.96M |
| Cash, Cash Equivalents and Short-Term Investments | 3.00M | 40.44M | 76.11M | 193.36M | 306.92M |
| Total Debt | 334.90M | 94.87M | 93.19M | 78.43M | 58.29M |
| Total Liabilities | 504.66M | 532.70M | 462.30M | 468.46M | 418.05M |
| Stockholders Equity | -271.11M | -326.38M | -160.33M | -61.28M | 34.44M |
Cash Flow | |||||
| Free Cash Flow | -158.89M | -158.89M | -234.16M | -228.44M | -23.67M |
| Operating Cash Flow | -158.31M | -158.31M | -224.20M | -175.37M | 10.14M |
| Investing Cash Flow | 27.00K | 27.00K | 3.40M | -33.61M | -43.15M |
| Financing Cash Flow | 122.84M | 122.84M | 119.87M | 95.83M | 225.26M |
Agenus Technical Analysis
Positive
4.64
Price Trends
3.40
Positive
3.55
Positive
4.12
Positive
Market Momentum
0.31
Negative
69.38
Neutral
81.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGEN, the sentiment is Positive. The current price of 4.64 is above the 20-day moving average (MA) of 3.82, above the 50-day MA of 3.40, and above the 200-day MA of 4.12, indicating a bullish trend. The MACD of 0.31 indicates Negative momentum. The RSI at 69.38 is Neutral, neither overbought nor oversold. The STOCH value of 81.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AGEN.
Agenus Risk Analysis
Agenus disclosed 86 risk factors in its most recent earnings report. Agenus reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Agenus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $152.83M | 15.23 | 22.53% | ― | -67.38% | -1076.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $195.19M | -1.21 | -179.42% | ― | ― | 99.21% | |
46 Neutral | $185.46M | 811.87 | -0.04% | ― | -33.41% | 81.19% | |
46 Neutral | $127.74M | -2.91 | -1292.68% | ― | ― | ― | |
43 Neutral | $97.51M | -9.60 | -353.36% | ― | -10.36% | 42.36% | |
43 Neutral | $60.29M | -2.28 | -55.88% | ― | ― | 1.40% |
* Healthcare Sector Average
AGEN
Agenus
4.64
2.56
123.08%
INO
Inovio Pharmaceuticals
1.16
-0.58
-33.33%
ONCY
Oncolytics Biotech
1.06
0.50
88.95%
HURA
TuHURA Biosciences
2.96
-1.19
-28.67%
SPRO
Spero Therapeutics
2.68
1.93
255.44%
TIL
Instil Bio
8.90
-6.56
-42.43%
Agenus Corporate Events
Legal Proceedings
Agenus Securities Class Action Dismissed, Legal Risks Ease
Positive
Mar 26, 2026
On March 24, 2026, the U.S. District Court for the District of Massachusetts dismissed in its entirety a putative securities class action against Agenus Inc. and several current and former executives, which had alleged violations of federal securi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.